目的 以脂質(zhì)組學為基礎(chǔ)，深入剖析蒙藥保利爾膠囊在高脂血癥治療中的作用機制。方法 利用高脂飲食誘導構(gòu)建高脂血癥大鼠模型，造模成功后，將大鼠隨機分為對照組、高脂血癥模型組及保利爾膠囊低、中、高劑量（270、810、2 430 mg·kg^-1）組，持續(xù)給藥8周。采用非靶向脂質(zhì)組學技術(shù)，對大鼠血漿中的內(nèi)源性脂質(zhì)變化進行分析，探尋潛在的生物標志物及相關(guān)代謝通路。結(jié)果 脂質(zhì)組學結(jié)果表明，對照組、模型組與保利爾膠囊高劑量給藥組大鼠血漿中存在34種脂質(zhì)差異代謝物，涉及甘油磷脂、磷脂酰肌醇及甘油酯等代謝通路。結(jié)論 高脂飲食通過對甘油磷脂代謝產(chǎn)生影響進而導致高脂血癥，而保利爾膠囊的調(diào)血脂作用主要是通過調(diào)節(jié)甘油磷脂和亞油酸代謝來實現(xiàn)。同時驗證和補充代謝組學的研究結(jié)果，進一步強調(diào)甘油磷脂代謝在調(diào)節(jié)血脂過程中的關(guān)鍵作用。

Objective To analyze the mechanism of action of Mongolian drug Baolier Capsule in the treatment of hyperlipidemia based on lipidomics.Methods The rats were randomly divided into control group, hyperlipidemia model group and low, medium and high-dose (270, 810, 2 430 mg·kg^-1) Baolier Capsules groups after successful modeling, and the rats were continuously administered for eight weeks. Non-targeted lipidomics technology was used to analyze endogenous lipid changes in rat plasma to explore potential biomarkers and related metabolic pathways.Results The results of lipidomics showed that there were 34 lipid differential metabolites in the plasma of hyperlipidemic rats in control group, model group and high-dose administration group, involving metabolic pathways such as glycerophospholipids, phosphatidylinositol and glycerides.Conclusion High-fat diet can affect glycerophospholipid metabolism and lead to hyperlipidemia, and the hypolipidemic effect of Baolier Capsule is mainly achieved by regulating the metabolism of glycerol phospholipid and linoleic acid. Lipidomics effectively revealed the formation mechanism of hyperlipidemia and the improvement effect of Baolier Capsules, and at the same time verified and supplemented the findings of metabolomics, further emphasizing the key role of glycerophospholipid metabolism in the process of lowering blood lipids.

R285.5

國家自然科學青年基金項目（82204509）；國家重點研發(fā)計劃（2023YFA0913900）；通遼市科技計劃項目（TL2023YF010）；天津合成生物技術(shù)創(chuàng)新能力提升行動項目（TSBICIP-CXRC-073）